This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) who are interested in information on TECENTRIQ®. If you are a US healthcare professional click hereopens in a new tab
The product has received EMA approval. The registration status and approved product labels of TECENTRIQ® may not be the same in different countries. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.
This website has been updated according to the latest EMA approval in February 2021.
Together we can make an impact on patients’ lives. Let’s all connect for one purpose – giving our patients new hope.
Connecting
Roche is investing to bring personalised immunotherapy to people with cancer. TECENTRIQ is approved as monotherapy or in combination with other medicines in several cancer types. Click the links below to learn more.
TECENTRIQ binds directly to PD-L1, increasing the ability of the immune system to attack the tumour and reduce disease progression.
TECENTRIQ (atezolizumab)
The first approved anti-PD-L1 cancer immunotherapy
Introducing the proposed mechanism of action for TECENTRIQ (atezolizumab). The first approved anti PD-L1 cancer immunotherapy. Cancer immunotherapies are designed to work with the immune system to combat cancer. The cancer immunity cycle characterizes how a person’s own immune system can help protect the body against cancer. Through a series of complex interactions, the immune system can detect tumours and activate cytotoxic t-cells to infiltrate the tumour microenvironment and attack tumour cells. When functioning optimally the cancer immunity cycle is self-sustaining, however in patients with cancer this immunity cycle can be disrupted allowing for unchecked tumour growth. Among other factors this disruption can be caused by PD-L1, instead of a negative immune regulator that can be expressed in the tumour microenvironment. Cytotoxic T cells that enter the tumour microenvironment may be deactivated by PD-L1 on tumour cells and tumour infiltrating immune cells. When PD-L1 binds to its receptors PD-1 or B7.1 on T cells, the T cells may be rendered inactive. As a result, anti-tumour immune activity may be suppressed in the tumour microenvironment causing disruption in the cancer immunity cycle. TECENTRIQ is the first approved anti PD-L1 cancer immunotherapy. TECENTRIQ targets PD-L1 in the tumour microenvironment. A key site of T cell deactivation. The proposed mechanism of action of TECENTRIQ has three distinct features. The first feature direct, TECENTRIQ is designed to bind directly to PD-L1 on tumour cells and tumour infiltrating immune cells in the tumour microenvironment. The second feature, complete. TECENTRIQ provides a dual blockade by preventing PD-L1 from binding to both the PD-1 and B7.1 receptors. Blocking interaction with PD-1 can reinvigorate suppressed T cells to kill cancer cells. Blocking interaction with B7.1 can enhance T cell priming and activation in the lymph node.
The third feature, selective. In normal tissues TECENTRIQ may help minimize autoimmune reactions. TECENTRIQ spares interactions between PD-1 and PD-L2 potentially preserving immune homeostasis in normal tissue. In clinical trials blocking PD-L1 from binding to its receptors resulted in tumour shrinkage. TECENTRIQ provides direct and complete blockade of PD-L1 interactions while selectively sparing PD-L2 interactions. This can restore antitumor T cell activity and enhanced T cell priming within the cancer immunity cycle.
For more information about TECENTRIQ the first approved anti PD-L1 cancer immunotherapy. Please contact your Roche representative.
ASIA
Select a Country
By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.
AFRICA
Select a Country
No country found.
By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.
OCEANIA
Select a Country
By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.
Global select
Select a Country
By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.
NORTH AMERICA
Select a Country
United States of America
By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.
EUROPE
Select a Country
By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.
SOUTH AMERICA
Select a Country
By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.
The pins are only for illustrative purpose and do not represent countries or states.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
© 2024 F. Hoffmann-La Roche Ltd M-XX-00015560